XML 25 R15.htm IDEA: XBRL DOCUMENT
v3.22.2

Stockholder’s Deficit | 3 Months Ended
--- | ---
Mar. 31, 2022
Equity [Abstract] |
Stockholder’s Deficit | 9. Stockholder’s Deficit Issuance of Common Stock for Directors and Employees During the three months ended March 31, 2022, the Company granted 870,500 of shares to employees and directors with a fair value of $435,250. The shares vest over a two-year period. As of March 31, 2022, the Company issued 323,833 shares of common stock with a fair value of $173,535, or $0.54 per share, to members of the Company’ Board Directors and employees for services rendered. As of March 31, 2022, the aggregate amount of the unvested compensation was $261,714. Issuance of Common Stock for Services The Company did not issue shares for services during the three months ended March 31, 2022. During the three months ended March 31, 2021, the Company issued 381,896 shares of common stock with a fair value of $1,114,860, or $2.92 per share, to consultants for services rendered. Issuance of Common Stock for Acquisition of GameIQ During the three months ended March 31, 2022, the Company issued 600,000 shares of common stock with a fair value of $300,000, or $0.50 per share, as partial consideration paid on the acquisition of GameIQ (see Note 3). Issuance of Common Stock for Public Offering During the three months ended March 31, 2021, the Company received proceeds of $362,000 on the sale of 155,760 shares of common stock, at an average price of $2.32 per share, as part of a public offering. Summary of Stock Options A summary of stock options for the three months ended March 31, 2022, is as follows: Summary of Stock Options
|  |  |  |  | Weighted |
|  | Number |  |  | Average |
|  | of |  |  | Exercise |
|  | Options |  |  | Price |
Balance outstanding, December 31, 2021 |  |  | 187,116 |  |  |  | 12.38 |
Options granted |  |  | 461,000 |  |  |  | 1.43 |
Options exercised |  |  | - |  |  |  | - |
Options expired or forfeited |  |  | - |  |  |  | - |
Balance outstanding, March 31, 2022 |  |  | 648,116 |  |  | $ | 4.59 |
Balance exercisable, March 31, 2022 |  |  | 368,944 |  |  | $ | 6.98 |
On February 28, 2022, the Company, pursuant to the terms of its 2019 Stock Incentive Plan, approved options exercisable into 461,000 shares to be issued to its employees. Of the 461,000 stock options issued, 60,000 stock options had an exercise price of $1.00 per share, with vesting of 33% on date of issuance, and then 33% on each subsequent anniversary date. The remaining 400,000 stock options had an exercise price of $1.50 per share, with 160,000 stock options vesting on March 1, 2022, and 10,000 stock options vesting each month thereafter beginning on April 1, 2022. The stock options are exercisable at a weighted average price of $1.25 per share with an average life to expiration of approximately seven years. The total fair value of these options at grant date was approximately $243,000, which was determined using a Black-Scholes-Merton option pricing model with the following average assumption: stock price of $0.53 per share, expected term of 4.50 years, volatility of 270%, dividend rate of 0%, and weighted average risk-free interest rate of 1.81%. The expected term represents the weighted-average period of time that share option awards granted are expected to be outstanding giving consideration to vesting schedules and historical participant exercise behavior; the expected volatility is based upon historical volatility of the Company’s common stock; the expected dividend yield is based on the fact that the Company has not paid dividends in the past and does not expect to pay dividends in the future; and the risk-free interest rate is based on the U.S. Treasury yield curve in effect at the time of measurement corresponding with the expected term of the share option award. During the three months ended March 31, 2022, the Company recognized $101,000 of compensation expense relating to vested stock options. As of March 31, 2022, the aggregate amount of unvested compensation related to stock options was approximately $142,000 which will be recognized as an expense as the options vest in future periods through February 28, 2025. The weighted average remaining contractual life of common stock options outstanding and exercisable at March 31, 2022 was 6.72 years. Based on a fair market value of $1.00 per share on March 31, 2022, there was no intrinsic value attributed to exercisable but unexercised common stock options at March 31, 2022. Summary of Warrants A summary of warrants for the three months ended March 31, 2022, is as follows: Summary of Warrants
|  |  |  |  | Weighted |
|  | Number |  |  | Average |
|  | of |  |  | Exercise |
|  | Warrants |  |  | Price |
Balance outstanding, December 31, 2021 |  |  | 20,667 |  |  | $ | 9.00 |
Warrants granted |  |  | - |  |  |  | - |
Warrants exercised |  |  | - |  |  |  | - |
Warrants expired or forfeited |  |  | - |  |  |  | - |
Balance outstanding, March 31, 2022 |  |  | 20,667 |  |  | $ | 9.00 |
Balance exercisable, March 31, 2022 |  |  | 20,667 |  |  | $ | 9.00 |
The weighted average remaining contractual life of common stock warrants outstanding and exercisable at March 31, 2022 was 0.46 years. At March 31, 2022, all outstanding warrants are exercisable at $9.00 per common share. Based on a fair market value of $1.00 per share on March 31, 2022, there was no intrinsic value attributed to exercisable but unexercised common stock warrants at March 31, 2022.

X
- References No definition available. + Details
Name: | us-gaap_EquityAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 505 -URI https://asc.fasb.org/topic&trid=2208762 Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 505 -SubTopic 10 -Section 50 -Paragraph 13 -Subparagraph (b) -URI https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644 Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 505 -SubTopic 10 -Section 50 -Paragraph 13 -URI https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644 Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 505 -SubTopic 10 -Section 50 -Paragraph 14 -Subparagraph (c) -URI https://asc.fasb.org/extlink&oid=126973232&loc=SL123496171-112644 Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 505 -SubTopic 10 -Section 50 -Paragraph 14 -Subparagraph (b) -URI https://asc.fasb.org/extlink&oid=126973232&loc=SL123496171-112644 Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 505 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -URI https://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770 Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 505 -SubTopic 10 -Section 50 -Paragraph 18 -Subparagraph (d) -URI https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644 Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 505 -SubTopic 10 -Section 50 -Paragraph 13 -Subparagraph (g) -URI https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644 Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 505 -SubTopic 10 -Section 50 -Paragraph 18 -Subparagraph (a) -URI https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644 Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 505 -SubTopic 10 -Section 50 -Paragraph 13 -Subparagraph (h) -URI https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644 Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 505 -SubTopic 10 -Section 50 -Paragraph 14 -Subparagraph (a) -URI https://asc.fasb.org/extlink&oid=126973232&loc=SL123496171-112644 Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 505 -SubTopic 10 -Section 50 -Paragraph 18 -Subparagraph (b) -URI https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644 Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 505 -SubTopic 10 -Section 50 -Paragraph 16 -Subparagraph (b) -URI https://asc.fasb.org/extlink&oid=126973232&loc=SL123496180-112644 Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 505 -SubTopic 10 -Section 50 -Paragraph 13 -Subparagraph (i) -URI https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644 Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 235 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(e)(1)) -URI https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690 Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 815 -SubTopic 40 -Section 50 -Paragraph 6 -Subparagraph (a) -URI https://asc.fasb.org/extlink&oid=126731327&loc=SL126733271-114008 + Details
Name: | us-gaap_StockholdersEquityNoteDisclosureTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration